Hemophilia Market

Global Hemophilia Market Size, Trends & Analysis - Forecasts to 2028 By Type (Hemophilia A, Hemophilia B, and Others), By Treatment (On-demand, Cure, and Prophylaxis), By Therapy (Factor Replacement Therapy, Desmopressin & Fibrin Sealants, and Gene Therapy & Monoclonal Antibodies), By Distribution Channel (Hospital Pharmacies and Specialty Pharmacies), and By Region (North America, Asia Pacific, Central and South America, Europe, and Middle East and Africa), Competitive Landscape, Company Market Share Analysis, and Competitor Analysis

Category Healthcare

Format

This report was recently updated on April 22 2024 with the latest and most recent market numbers

Global Hemophilia Market Size

The global hemophilia market is projected to grow at a CAGR of 6.8% from 2023 to 2028.

Haemophilia is a genetic bleeding disorder, in which people lack specific clotting factors in their blood, resulting in prolonged and uncontrollable bleeding. Haemophilia A (lack of factor VIII) and haemophilia B (lack of factor IX) are the two most common types. Infusions are used to replace missing clotting factors, in order to prevent or manage bleeding episodes.

Advancements in medical research, rising incidence of hemophilia, and increasing awareness about the diagnosis of haemophilia are expected to support the market growth during the forecast period. Additionally, factors such as technology innovation, expanded healthcare infrastructure, and the growing adoption of treatments by patients contribute to the overall growth of the global hemophilia market.

The rising global prevalence of hemophilia has led to a larger patient population, creating a higher demand for treatment options. Specialized haemophilia treatment centres enhance patient accessibility to top-notch healthcare services. As patients and healthcare providers increasingly accept and adopt these treatments, the market is expected to witness growth. Increased awareness and early diagnosis of hemophilia also play a vital role in boosting treatment adoption rates.

Furthermore, supportive healthcare policies and government funding assistance enable better access to treatment, driving the market growth. Ongoing research and development efforts continually introduce new and more effective treatments, expanding the market's offerings.

global hemophilia market

Global Hemophilia Market: By Type

Hemophilia B is expected to be the fastest-growing segment in the market from 2023-2028. The progress in treatment options, particularly the development of improved factor IX replacement products, will likely boost the demand for therapies targeted at hemophilia B. Additionally, gene therapy innovations for hemophilia B have shown promising potential, attracting significant interest and investment. Rising awareness and improved diagnostic methods are expected to result in earlier detection and treatment, contributing to segment growth.

Hemophilia A segment is projected to hold the largest share of the market. Insufficient levels of blood clotting factor VIII cause this genetic disorder. The segment growth is attributed to the rising incidence of hemophilia A and government efforts to introduce treatments in significant markets such as the U.S., Europe, and Japan.

Global Hemophilia Market: By Treatment Type

Cure segment is anticipated to be the fastest-growing segment in the market from 2023-2028. Factors contributing to its rapid growth include advancements in medical research and technology to develop highly effective and precise curative therapies. Additionally, favourable regulatory frameworks and government initiatives aimed at promoting the accessibility and affordability of curative treatments may further boost the growth of this segment.

Prophylaxis segment is expected to be the largest segment during the forecast period. Individuals with severe hemophilia are recommended for prophylaxis treatments. However, there is a new treatment approach involving regular infusions of clotting factor concentrates that is expected to drive growth of the segment. One such example is the rising use of the bi-specific antibody product Helimbra (emicizumab) to address clotting factor FVIII deficiency, which is contributing to the growth of the market. Moreover, these groundbreaking treatments are expected to improve the overall quality of life for patients.

Global Hemophilia Market: By Therapy

The gene therapy & monoclonal antibodies segment is anticipated to be the fastest-growing segment in the market from 2023-2028. Advancements in gene therapy research have paved the way for potentially curative treatments, offering hope for improved long-term outcomes and reduced reliance on factor replacement therapies. Additionally, the efficacy and convenience of monoclonal antibodies, such as Emicizumab have demonstrated promising results in managing hemophilia with less frequent dosing compared to traditional treatments.

The factor replacement segment is anticipated to hold the largest share of the market. Factor replacement therapy is considered a standard treatment for individuals with hemophilia type A and B, allowing the replenishment of deficient clotting factors. Type A patients are treated with Factor VIII replacement products, while Type B patients receive Factor IX replacement products. These therapeutic products can be derived from plasma or produced through recombinant DNA technology.

Global Hemophilia Market: By Distribution Channel

The hospital pharmacies segment is anticipated to be the fastest-growing segment in the market from 2023-2028. This growth is attributed to the approval of gene therapy, which is predominantly administered in hospitals due to the need for continuous monitoring of potential side effects. This factor is anticipated to drive the growth of the hospital pharmacies segment. Moreover, certain hemophilia treatment centers (HTCs) are also affiliated with hospitals, further contributing to the segment growth.

The specialty pharmacies segment is expected to hold the largest share of the market. Hemophilia, being a rare and intricate disorder, poses a scarcity of qualified professionals specialized in providing treatment. In the United States, a majority of hemophilia patients seek care at designated "hemophilia treatment centers" or HTCs due to their expertise in managing this condition. These HTCs typically consist of multidisciplinary teams well-versed in hemophilia management and rely heavily on specialty pharmacies for their drug supplies.

asia pacific hemophilia market

Global Hemophilia Market: By Region

North America is expected to be the largest market over the forecast period. The primary reasons boosting the regional market growth are the increasing acceptance of patient treatments, favourable financial support, existence of specialized centres focused on hemophilia treatment, and the rising incidence of Hemophilia.

Asia Pacific is predicted to witness rapid growth during the forecast period. This is attributed to increasing awareness of hemophilia, rising healthcare expenditure, expansion of healthcare infrastructure, a growing patient pool, favorable government initiatives, and increasing research and development activities. These factors collectively create a favorable environment for the growth of the hemophilia treatment market in the Asia Pacific.

Global Hemophilia Market Share and Competitor Analysis

Takeda Pharmaceutical Company Limited, CSL Behring, Pfizer, Inc., Bayer AG, BioMarin, Spark Therapeutics, Inc., Sanofi, F. Hoffmann La-Roche Ltd., Novo Nordisk A/S., and Octapharma AG. among others, are some of the key players operating in the global hemophilia market.

Please note: This is not an exhaustive list of companies profiled in the report.

1 STRATEGIC INSIGHTS ON NEW REVENUE POCKETS

1.1 Strategic Opportunity & Attractiveness Analysis

1.1.1 Hot Revenue Pockets

1.1.2 Market Attractiveness Score

1.1.3 Revenue Impacting Opportunity

1.1.4 High Growing Region/Country

1.1.5 Competitor Analysis

1.1.6 Consumer Analysis

1.2 Global Market Estimates' View

1.3 Strategic Insights across Business Functions

1.3.1 For Chief Executive Officers

1.3.2 For Chief Marketing Officers

1.3.3 For Chief Strategy Officers

1.4 Evaluate the Potential of your Existing Business Lines vs. New Lines to Enter Into

2 TECHNOLOGICAL TRENDS

2.1 Technological Adoption Rate

2.2 Current Trend Impact Analysis

2.3 Future Trend Impact Analysis

2.4 Data Metrics on Feed Stocks

3 GLOBAL MARKET OUTLOOK

3.1 Market Pyramid Analysis

3.1.1 Introduction

3.1.2 Adjacent Market Opportunities

3.1.3 Ancillary Market Opportunities

3.2 Demand Side Analysis

3.2.1 Market Drivers: Impact Analysis

3.2.2 Market Restraints: Impact Analysis

3.2.3 Market Opportunities: Impact Analysis

3.2.4 Market Challenges: Impact Analysis

3.3 Supply Side Analysis

3.3.1 Porter’s Five Forces Analysis

3.3.1.1 Threat of New Entrants

3.3.1.2 Threat of New Substitutes

3.3.1.3 Bargaining Power of Suppliers

3.3.1.4 Bargaining Power of Buyers

3.3.1.5 Intensity of Competitive Rivalry

3.3.2 SWOT Analysis; By Factor (Political & Legal, Economic, and Technological)

3.3.2.1 Political Landscape

3.3.2.2 Economic Landscape

3.3.2.3 Social Landscape

3.3.2.4 Technology Landscape

3.3.3 Value Chain Analysis

3.3.4 Trend Analysis

3.3.5 Gap Analysis

3.3.6 Cost Analysis

4 GLOBAL HEMOPHILIA MARKET, BY TYPE

4.1 Introduction

4.2 Hemophilia Market: Type Scope Key Takeaways

4.3 Revenue Growth Analysis, 2022 & 2028

4.4 Hemophilia A

4.4.1 Hemophilia A Market Estimates and Forecast, 2020-2028 (USD Million)

4.5 Hemophilia B

4.5.1 Hemophilia B Market Estimates and Forecast, 2020-2028 (USD Million)

4.6 Others

4.6.1 Others Market Estimates and Forecast, 2020-2028 (USD Million)

5 GLOBAL HEMOPHILIA MARKET, BY TREATMENT

5.1 Introduction

5.2 Hemophilia Market: Treatment Technique Scope Key Takeaways

5.3 Revenue Growth Analysis, 2022 & 2028

5.4 On-demand

5.4.1 On-demand Market Estimates and Forecast, 2020-2028 (USD Million)

5.5 Cure

5.5.1 Cure Market Estimates and Forecast, 2020-2028 (USD Million)

5.6 Prophylaxis

5.6.1 Prophylaxis Market Estimates and Forecast, 2020-2028 (USD Million)

6 GLOBAL HEMOPHILIA MARKET, BY THERAPY

6.1 Introduction

6.2 Hemophilia Market: Therapy Scope Key Takeaways

6.3 Revenue Growth Analysis, 2022 & 2028

6.4 Factor Replacement By Therapy

6.4.1 Factor Replacement By Therapy Market Estimates and Forecast, 2020-2028 (USD Million)

6.5 Desmopressin & Fibrin Sealants

6.5.1 Desmopressin & Fibrin Sealants Market Estimates and Forecast, 2020-2028 (USD Million)

6.6 Gene By Therapy & Monoclonal Antibodies

6.6.1 Gene By Therapy & Monoclonal Antibodies Market Estimates and Forecast, 2020-2028 (USD Million)

7 GLOBAL HEMOPHILIA MARKET, BY DISTRIBUTION CHANNEL

7.1 Introduction

7.2 Hemophilia Market: Distribution Channel Scope Key Takeaways

7.3 Revenue Growth Analysis, 2022 & 2028

7.4 Hospital Pharmacies

7.4.1 Hospital Pharmacies Market Estimates and Forecast, 2020-2028 (USD Million)

7.5 Specialty Pharmacies

7.5.1 Specialty Pharmacies Market Estimates and Forecast, 2020-2028 (USD Million)

8 GLOBAL HEMOPHILIA MARKET, BY REGION

8.1 Introduction

8.2 North America Hemophilia Market Estimates and Forecast, 2020-2028 (USD Million)

8.2.1 By Type

8.2.2 By Treatment

8.2.3 By Therapy

8.2.4 By Distribution Channel

8.2.5 By Country

8.2.5.1 U.S. Hemophilia Market Estimates and Forecast, 2020-2028 (USD Million)

8.2.5.1.1 By Type

8.2.5.1.2 By Treatment

8.2.5.1.3 By Therapy

8.2.5.1.4 By Distribution Channel

8.2.5.2 Canada Hemophilia Market Estimates and Forecast, 2020-2028 (USD Million)

8.2.5.2.1 By Type

8.2.5.2.2 By Treatment

8.2.5.2.3 By Therapy

8.2.5.2.4 By Distribution Channel

8.2.5.3 Mexico Hemophilia Market Estimates and Forecast, 2020-2028 (USD Million)

8.2.5.3.1 By Type

8.2.5.3.2 By Treatment

8.2.5.3.3 By Therapy

8.2.5.3.4 By Distribution Channel

8.3 Europe Hemophilia Market Estimates and Forecast, 2020-2028 (USD Million)

8.3.1 By Type

8.3.2 By Treatment

8.3.3 By Therapy

8.3.4 By Distribution Channel

8.3.5 By Country

8.3.5.1 Germany Hemophilia Market Estimates and Forecast, 2020-2028 (USD Million)

8.3.5.1.1 By Type

8.3.5.1.2 By Treatment

8.3.5.1.3 By Therapy

8.3.5.1.4 By Distribution Channel

8.3.5.2 U.K. Presered Flowers Market Estimates and Forecast, 2020-2028 (USD Million)

8.3.5.2.1 By Type

8.3.5.2.2 By Treatment

8.3.5.2.3 By Therapy

8.3.5.2.4 By Distribution Channel

8.3.5.3 France Hemophilia Market Estimates and Forecast, 2020-2028 (USD Million)

8.3.5.3.1 By Type

8.3.5.3.2 By Treatment

8.3.5.3.3 By Therapy

8.3.5.3.4 By Distribution Channel

8.3.5.4 Italy Hemophilia Market Estimates and Forecast, 2020-2028 (USD Million)

8.3.5.4.1 By Type

8.3.5.4.2 By Treatment

8.3.5.4.3 By Therapy

8.3.5.4.4 By Distribution Channel

8.3.5.5 Spain Hemophilia Market Estimates and Forecast, 2020-2028 (USD Million)

8.3.5.5.1 By Type

8.3.5.5.2 By Treatment

8.3.5.5.3 By Therapy

8.3.5.5.4 By Distribution Channel

8.3.5.6 Netherlands Hemophilia Market Estimates and Forecast, 2020-2028 (USD Million)

8.3.5.6.1 By Type

8.3.5.6.2 By Treatment

8.3.5.6.3 By Therapy

8.3.5.6.4 By Distribution Channel

8.3.5.7 Rest of Europe Hemophilia Market Estimates and Forecast, 2020-2028 (USD Million)

8.3.5.7.1 By Type

8.3.5.7.2 By Treatment

8.3.5.7.3 By Therapy

8.3.5.7.4 By Distribution Channel

8.4 Asia Pacific Hemophilia Market Estimates and Forecast, 2020-2028 (USD Million)

8.4.1 By Type

8.4.2 By Treatment

8.4.3 By Therapy

8.4.4 By Distribution Channel

8.4.5 By Country

8.4.5.1 China Hemophilia Market Estimates and Forecast, 2020-2028 (USD Million)

8.4.5.1.1 By Type

8.4.5.1.2 By Treatment

8.4.5.1.3 By Therapy

8.4.5.1.4 By Distribution Channel

8.4.5.2 Japan Hemophilia Market Estimates and Forecast, 2020-2028 (USD Million)

8.4.5.2.1 By Type

8.4.5.2.2 By Treatment

8.4.5.2.3 By Therapy

8.4.5.2.4 By Distribution Channel

8.4.5.3 India Hemophilia Market Estimates and Forecast, 2020-2028 (USD Million)

8.4.5.3.1 By Type

8.4.5.3.2 By Treatment

8.4.5.3.3 By Therapy

8.4.5.3.4 By Distribution Channel

8.4.5.4 South Korea Hemophilia Market Estimates and Forecast, 2020-2028 (USD Million)

8.4.5.4.1 By Type

8.4.5.4.2 By Treatment

8.4.5.4.3 By Therapy

8.4.5.4.4 By Distribution Channel

8.4.5.5 Singapore Hemophilia Market Estimates and Forecast, 2020-2028 (USD Million)

8.4.5.5.1 By Type

8.4.5.5.2 By Treatment

8.4.5.5.3 By Therapy

8.4.5.5.4 By Distribution Channel

8.4.5.6 Malaysia Hemophilia Market Estimates and Forecast, 2020-2028 (USD Million)

8.4.5.6.1 By Type

8.4.5.6.2 By Treatment

8.4.5.6.3 By Therapy

8.4.5.6.4 By Distribution Channel

8.4.5.7 Thailand Hemophilia Market Estimates and Forecast, 2020-2028 (USD Million)

8.4.5.7.1 By Type

8.4.5.7.2 By Treatment

8.4.5.7.3 By Therapy

8.4.5.7.4 By Distribution Channel

8.4.5.8 Indonesia Hemophilia Market Estimates and Forecast, 2020-2028 (USD Million)

8.4.5.8.1 By Type

8.4.5.8.2 By Treatment

8.4.5.8.3 By Therapy

8.4.5.8.4 By Distribution Channel

8.4.5.9 Vietnam Hemophilia Market Estimates and Forecast, 2020-2028 (USD Million)

8.4.5.9.1 By Type

8.4.5.9.2 By Treatment

8.4.5.9.3 By Therapy

8.4.5.9.4 By Distribution Channel

8.4.5.10 Taiwan Hemophilia Market Estimates and Forecast, 2020-2028 (USD Million)

8.4.5.10.1 By Type

8.4.5.10.2 By Treatment

8.4.5.10.3 By Therapy

8.4.5.10.4 By Distribution Channel

8.4.5.11 Rest of Asia Pacific Hemophilia Market Estimates and Forecast, 2020-2028 (USD Million)

8.4.5.11.1 By Type

8.4.5.11.2 By Treatment

8.4.5.11.3 By Therapy

8.4.5.11.4 By Distribution Channel

8.5 Middle East and Africa Hemophilia Market Estimates and Forecast, 2020-2028 (USD Million)

8.5.1 By Type

8.5.2 By Treatment

8.5.3 By Therapy

8.5.4 By Distribution Channel

8.5.5 By Country

8.5.5.1 Saudi Arabia Hemophilia Market Estimates and Forecast, 2020-2028 (USD Million)

8.5.5.1.1 By Type

8.5.5.1.2 By Treatment

8.5.5.1.3 By Therapy

8.5.5.1.4 By Distribution Channel

8.5.5.2 U.A.E. Hemophilia Market Estimates and Forecast, 2020-2028 (USD Million)

8.5.5.2.1 By Type

8.5.5.2.2 By Treatment

8.5.5.2.3 By Therapy

8.5.5.2.4 By Distribution Channel

8.5.5.3 Israel Hemophilia Market Estimates and Forecast, 2020-2028 (USD Million)

8.5.4.3.1 By Type

8.5.4.3.2 By Treatment

8.5.4.3.3 By Therapy

8.5.5.3.4 By Distribution Channel

8.5.5.4 South Africa Hemophilia Market Estimates and Forecast, 2020-2028 (USD Million)

8.5.5.4.1 By Type

8.5.5.4.2 By Treatment

8.5.5.4.3 By Therapy

8.5.5.4.4 By Distribution Channel

8.5.5.5 Rest of Middle East and Africa Hemophilia Market Estimates and Forecast, 2020-2028 (USD Million)

8.5.5.5.1 By Type

8.5.5.5.2 By Treatment

8.5.5.5.2 By Therapy

8.5.5.5.4 By Distribution Channel

8.6 Central and South America Hemophilia Market Estimates and Forecast, 2020-2028 (USD Million)

8.6.1 By Type

8.6.2 By Treatment

8.6.3 By Therapy

8.6.4 By Distribution Channel

8.6.5 By Country

8.6.5.1 Brazil Hemophilia Market Estimates and Forecast, 2020-2028 (USD Million)

8.6.5.1.1 By Type

8.6.5.1.2 By Treatment

8.6.5.1.3 By Therapy

8.6.5.1.4 By Distribution Channel

8.6.5.2 Argentina Hemophilia Market Estimates and Forecast, 2020-2028 (USD Million)

8.6.5.2.1 By Type

8.6.5.2.2 By Treatment

8.6.5.2.3 By Therapy

8.6.5.2.4 By Distribution Channel

8.6.5.3 Chile Hemophilia Market Estimates and Forecast, 2020-2028 (USD Million)

8.6.5.3.1 By Type

8.6.5.3.2 By Treatment

8.6.5.3.3 By Therapy

8.6.5.5.4 By Distribution Channel

8.6.5.4 Rest of Central and South America Hemophilia Market Estimates and Forecast, 2020-2028 (USD Million)

8.6.5.4.1 By Type

8.6.5.4.2 By Treatment

8.6.5.4.3 By Therapy

8.6.5.4.4 By Distribution Channel

9 COMPETITIVE LANDCAPE

9.1 Company Market Share Analysis

9.2 Four Quadrant Positioning Matrix

9.2.1 Market Leaders

9.2.2 Market Visionaries

9.2.3 Market Challengers

9.2.4 Niche Market Players

9.3.4 Rest of the World

9.4 Company Profiles

9.4.1 Takeda Pharmaceutical Company Limited

9.4.1.1 Business Description & Financial Analysis

9.4.1.2 SWOT Analysis

9.4.1.3 Products & Services Offered

9.4.1.4 Strategic Alliances between Business Partners

9.4.2 CSL Behring

9.4.2.1 Business Description & Financial Analysis

9.4.2.2 SWOT Analysis

9.4.2.3 Products & Services Offered

9.4.2.4 Strategic Alliances between Business Partners

9.4.3 Pfizer, Inc.

9.4.3.1 Business Description & Financial Analysis

9.4.3.2 SWOT Analysis

9.4.3.3 Products & Services Offered

9.4.3.4 Strategic Alliances between Business Partners

9.4.4 Bayer AG

9.4.4.1 Business Description & Financial Analysis

9.4.4.2 SWOT Analysis

9.4.4.3 Products & Services Offered

9.4.4.4 Strategic Alliances between Business Partners

9.4.5 BioMarin

9.4.5.1 Business Description & Financial Analysis

9.4.5.2 SWOT Analysis

9.4.5.3 Products & Services Offered

9.4.5.4 Strategic Alliances between Business Partners

9.4.6 Sanofi

9.4.6.1 Business Description & Financial Analysis

9.4.6.2 SWOT Analysis

9.4.6.3 Products & Services Offered

9.4.6.4 Strategic Alliances between Business Partners

9.4.7 Spark Therapeutics, Inc.

9.4.7.1 Business Description & Financial Analysis

9.4.7.2 SWOT Analysis

9.4.7.3 Products & Services Offered

9.4.8.4 Strategic Alliances between Business Partners

9.4.8 F. Hoffmann La-Roche Ltd.

9.4.8.1 Business Description & Financial Analysis

9.4.8.2 SWOT Analysis

9.4.8.3 Products & Services Offered

9.4.8.4 Strategic Alliances between Business Partners

9.4.9 Novo Nordisk A/S.

9.4.9.1 Business Description & Financial Analysis

9.4.9.2 SWOT Analysis

9.4.9.3 Products & Services Offered

9.4.9.4 Strategic Alliances between Business Partners

9.4.10 Octapharma AG.

9.4.10.1 Business Description & Financial Analysis

9.4.10.2 SWOT Analysis

9.4.10.3 Products & Services Offered

9.4.10.4 Strategic Alliances between Business Partners

9.4.11 Other Companies

9.4.11.1 Business Description & Financial Analysis

9.4.11.2 SWOT Analysis

9.4.11.3 Products & Services Offered

9.4.11.4 Strategic Alliances between Business Partners

10 RESEARCH METHODOLOGY

10.1 Market Introduction

10.1.1 Market Definition

10.1.2 Market Scope & Segmentation

10.2 Information Procurement

10.2.1 Secondary Research

10.2.1.1 Purchased Databases

10.2.1.2 GMEs Internal Data Repository

10.2.1.3 Secondary Resources & Third Party Perspectives

10.2.1.4 Company Information Sources

10.2.2 Primary Research

10.2.2.1 Various Types of Respondents for Primary Interviews

10.2.2.2 Number of Interviews Conducted throughout the Research Process

10.2.2.3 Primary Stakeholders

10.2.2.4 Discussion Guide for Primary Participants

10.2.3 Expert Panels

10.2.3.1 Expert Panels Across 30+ Industry

10.2.4 Paid Local Experts

10.2.4.1 Paid Local Experts Across 30+ Industry Across each Region

10.3 Market Estimation

10.3.1 Top-Down Approach

10.3.1.1 Macro-Economic Indicators Considered

10.3.1.2 Micro-Economic Indicators Considered

10.3.2 Bottom Up Approach

10.3.2.1 Company Share Analysis Approach

10.3.2.2 Estimation of Potential Product Sales

10.4 Data Triangulation

10.4.1 Data Collection

10.4.2 Time Series, Cross Sectional & Panel Data Analysis

10.4.3 Cluster Analysis

10.5 Analysis and Output

10.5.1 Inhouse AI Based Real Time Analytics Tool

10.5.2 Output From Desk & Primary Research

10.6 Research Assumptions & Limitations

10.7.1 Research Assumptions

10.7.2 Research Limitations

LIST OF TABLES

1 Global Hemophilia Market, By Type, 2020-2028 (USD Mllion)

2 Hemophilia A Market, By Region, 2020-2028 (USD Mllion)

3 Hemophilia B Market, By Region, 2020-2028 (USD Mllion)

4 Others Market, By Region, 2020-2028 (USD Mllion)

5 Global Hemophilia Market, By Treatment, 2020-2028 (USD Mllion)

6 On-demand Market, By Region, 2020-2028 (USD Mllion)

7 Cure Market, By Region, 2020-2028 (USD Mllion)

8 Prophylaxis Market, By Region, 2020-2028 (USD Mllion)

9 Global Hemophilia Market, By Therapy, 2020-2028 (USD Mllion)

10 Factor Replacement By Therapy Market, By Region, 2020-2028 (USD Mllion)

11 Desmopressin & Fibrin Sealants Market, By Region, 2020-2028 (USD Mllion)

12 Gene By Therapy & Monoclonal Antibodies Market, By Region, 2020-2028 (USD Mllion)

13 Global Hemophilia Market, By DISTRIBUTION CHANNEL, 2020-2028 (USD Mllion)

14 Hospital Pharmacies Market, By Region, 2020-2028 (USD Mllion)

15 Specialty Pharmacies Market, By Region, 2020-2028 (USD Mllion)

16 Regional Analysis, 2020-2028 (USD Mllion)

17 North America Hemophilia Market, By Type, 2020-2028 (USD Million)

18 North America Hemophilia Market, By Treatment, 2020-2028 (USD Million)

19 North America Hemophilia Market, By Therapy, 2020-2028 (USD Million)

20 North America Hemophilia Market, By Distribution channel, 2020-2028 (USD Million)

21 North America Hemophilia Market, By Country, 2020-2028 (USD Million)

22 U.S Hemophilia Market, By Type, 2020-2028 (USD Million)

23 U.S Hemophilia Market, By Treatment, 2020-2028 (USD Million)

24 U.S Hemophilia Market, By Therapy, 2020-2028 (USD Million)

25 U.S Hemophilia Market, By Distribution channel, 2020-2028 (USD Million)

26 Canada Hemophilia Market, By Type, 2020-2028 (USD Million)

27 Canada Hemophilia Market, By Treatment, 2020-2028 (USD Million)

28 Canada Hemophilia Market, By Therapy, 2020-2028 (USD Million)

29 CANADA Hemophilia Market, By Distribution channel, 2020-2028 (USD Million)

30 Mexico Hemophilia Market, By Type, 2020-2028 (USD Million)

31 Mexico Hemophilia Market, By Treatment, 2020-2028 (USD Million)

32 Mexico Hemophilia Market, By Therapy, 2020-2028 (USD Million)

33 mexico Hemophilia Market, By Distribution channel, 2020-2028 (USD Million)

34 Europe Hemophilia Market, By Type, 2020-2028 (USD Million)

35 Europe Hemophilia Market, By Treatment, 2020-2028 (USD Million)

36 Europe Hemophilia Market, By Therapy, 2020-2028 (USD Million)

37 europe Hemophilia Market, By Distribution channel, 2020-2028 (USD Million)

38 Germany Hemophilia Market, By Type, 2020-2028 (USD Million)

39 Germany Hemophilia Market, By Treatment, 2020-2028 (USD Million)

40 Germany Hemophilia Market, By Therapy, 2020-2028 (USD Million)

41 germany Hemophilia Market, By Distribution channel, 2020-2028 (USD Million)

42 UK Hemophilia Market, By Type, 2020-2028 (USD Million)

43 UK Hemophilia Market, By Treatment, 2020-2028 (USD Million)

44 UK Hemophilia Market, By Therapy, 2020-2028 (USD Million)

45 U.kHemophilia Market, By Distribution channel, 2020-2028 (USD Million)

46 France Hemophilia Market, By Type, 2020-2028 (USD Million)

47 France Hemophilia Market, By Treatment, 2020-2028 (USD Million)

48 France Hemophilia Market, By Therapy, 2020-2028 (USD Million)

49 france Hemophilia Market, By Distribution channel, 2020-2028 (USD Million)

50 Italy Hemophilia Market, By Type, 2020-2028 (USD Million)

51 Italy Hemophilia Market, By T Preservation Technique Type, 2020-2028 (USD Million)

52 Italy Hemophilia Market, By Therapy, 2020-2028 (USD Million)

53 italy Hemophilia Market, By Distribution channel, 2020-2028 (USD Million)

54 Spain Hemophilia Market, By Type, 2020-2028 (USD Million)

55 Spain Hemophilia Market, By Treatment, 2020-2028 (USD Million)

56 Spain Hemophilia Market, By Therapy, 2020-2028 (USD Million)

57 spain Hemophilia Market, By Distribution channel, 2020-2028 (USD Million)

58 Rest Of Europe Hemophilia Market, By Type, 2020-2028 (USD Million)

59 Rest Of Europe Hemophilia Market, By Treatment, 2020-2028 (USD Million)

60 Rest of Europe Hemophilia Market, By Therapy, 2020-2028 (USD Million)

61 REST OF EUROPE Hemophilia Market, By Distribution channel, 2020-2028 (USD Million)

62 Asia Pacific Hemophilia Market, By Type, 2020-2028 (USD Million)

63 Asia Pacific Hemophilia Market, By Treatment, 2020-2028 (USD Million)

64 Asia Pacific Hemophilia Market, By Therapy, 2020-2028 (USD Million)

65 asia Hemophilia Market, By Distribution channel, 2020-2028 (USD Million)

66 Asia Pacific Hemophilia Market, By Country, 2020-2028 (USD Million)

67 China Hemophilia Market, By Type, 2020-2028 (USD Million)

68 China Hemophilia Market, By Treatment, 2020-2028 (USD Million)

69 China Hemophilia Market, By Therapy, 2020-2028 (USD Million)

70 china Hemophilia Market, By Distribution channel, 2020-2028 (USD Million)

71 India Hemophilia Market, By Type, 2020-2028 (USD Million)

72 India Hemophilia Market, By Treatment, 2020-2028 (USD Million)

73 India Hemophilia Market, By Therapy, 2020-2028 (USD Million)

74 india Hemophilia Market, By Distribution channel, 2020-2028 (USD Million)

75 Japan Hemophilia Market, By Type, 2020-2028 (USD Million)

76 Japan Hemophilia Market, By Treatment, 2020-2028 (USD Million)

77 Japan Hemophilia Market, By Therapy, 2020-2028 (USD Million)

78 japan Hemophilia Market, By Distribution channel, 2020-2028 (USD Million)

79 South Korea Hemophilia Market, By Type, 2020-2028 (USD Million)

80 South Korea Hemophilia Market, By Treatment, 2020-2028 (USD Million)

81 South Korea Hemophilia Market, By Therapy, 2020-2028 (USD Million)

82 south korea Hemophilia Market, By Distribution channel, 2020-2028 (USD Million)

83 Middle East and Africa Hemophilia Market, By Type, 2020-2028 (USD Million)

84 Middle East and Africa Hemophilia Market, By Treatment, 2020-2028 (USD Million)

85 Middle East and Africa Hemophilia Market, By Therapy, 2020-2028 (USD Million)

86 MIDDLE EAST AND AFRICA Hemophilia Market, By Distribution channel, 2020-2028 (USD Million)

87 Middle East and Africa Hemophilia Market, By Country, 2020-2028 (USD Million)

88 Saudi Arabia Hemophilia Market, By Type, 2020-2028 (USD Million)

89 Saudi Arabia Hemophilia Market, By Treatment, 2020-2028 (USD Million)

90 Saudi Arabia Hemophilia Market, By Therapy, 2020-2028 (USD Million)

91 saudi arabia Hemophilia Market, By Distribution channel, 2020-2028 (USD Million)

92 UAE Hemophilia Market, By Type, 2020-2028 (USD Million)

93 UAE Hemophilia Market, By Treatment, 2020-2028 (USD Million)

94 UAE Hemophilia Market, By Therapy, 2020-2028 (USD Million)

95 uae Hemophilia Market, By Distribution channel, 2020-2028 (USD Million)

96 Central and South America Hemophilia Market, By Type, 2020-2028 (USD Million)

97 Central and South America Hemophilia Market, By Treatment, 2020-2028 (USD Million)

98 Central and South America Hemophilia Market, By Therapy, 2020-2028 (USD Million)

99 CENTRAL AND SOUTH AMERICA Hemophilia Market, By Distribution channel, 2020-2028 (USD Million)

100 Central and South America Hemophilia Market, By Country, 2020-2028 (USD Million)

101 Brazil Hemophilia Market, By Type, 2020-2028 (USD Million)

102 Brazil Hemophilia Market, By Treatment, 2020-2028 (USD Million)

103 Brazil Hemophilia Market, By Therapy, 2020-2028 (USD Million)

104 brazil Hemophilia Market, By Distribution channel, 2020-2028 (USD Million)

105 Takeda Pharmaceutical Company Limited: Products & Services Offering

106 CSL Behring: Products & Services Offering

107 Pfizer, Inc.: Products & Services Offering

108 Bayer AG: Products & Services Offering

109 BioMarin: Products & Services Offering

110 SANOFI: Products & Services Offering

111 Spark Therapeutics, Inc. : Products & Services Offering

112 F. Hoffmann La-Roche Ltd.: Products & Services Offering

113 Novo Nordisk A/S., Inc: Products & Services Offering

114 Octapharma AG.: Products & Services Offering

115 Other Companies: Products & Services Offering

LIST OF FIGURES

1 Global Hemophilia Market Overview

2 Global Hemophilia Market Value From 2020-2028 (USD Mllion)

3 Global Hemophilia Market Share, By Type (2022)

4 Global Hemophilia Market Share, By Treatment (2022)

5 Global Hemophilia Market Share, By Therapy (2022)

6 Global Hemophilia Market Share, By Distribution Channel (2022)

7 Global Hemophilia Market, By Region (Asia Pacific Market)

8 Technological Trends In Global Hemophilia Market

9 Four Quadrant Competitor Positioning Matrix

10 Impact Of Macro & Micro Indicators On The Market

11 Impact Of Key Drivers On The Global Hemophilia Market

12 Impact Of Challenges On The Global Hemophilia Market

13 Porter’s Five Forces Analysis

14 Global Hemophilia Market: By Type Scope Key Takeaways

15 Global Hemophilia Market, By Type Segment: Revenue Growth Analysis

16 Hemophilia A Market, By Region, 2020-2028 (USD Mllion)

17 Hemophilia B Market, By Region, 2020-2028 (USD Mllion)

18 Others Market, By Region, 2020-2028 (USD Mllion)

19 Global Hemophilia Market: By Treatment Scope Key Takeaways

20 Global Hemophilia Market, By Treatment Segment: Revenue Growth Analysis

21 On-demand Market, By Region, 2020-2028 (USD Mllion)

22 Cure Market, By Region, 2020-2028 (USD Mllion)

23 Prophylaxis Market, By Region, 2020-2028 (USD Mllion)

24 Global Hemophilia Market: By Therapy Scope Key Takeaways

25 Global Hemophilia Market, By Therapy Segment: Revenue Growth Analysis

26 Factor Replacement By Therapy Market, By Region, 2020-2028 (USD Mllion)

27 Desmopressin & Fibrin Sealants Market, By Region, 2020-2028 (USD Mllion)

28 Gene By Therapy & Monoclonal Antibodies Market, By Region, 2020-2028 (USD Mllion)

29 Global Hemophilia Market: By Distribution Channel Scope Key Takeaways

30 Global Hemophilia Market, By Distribution Channel Segment: Revenue Growth Analysis

31 Hospital Pharmacies Market, By Region, 2020-2028 (USD Mllion)

32 Specialty Pharmacies Market, By Region, 2020-2028 (USD Mllion)

33 Regional Segment: Revenue Growth Analysis

34 Global Hemophilia Market: Regional Analysis

35 North America Hemophilia Market Overview

36 North America Hemophilia Market, By Type

37 North America Hemophilia Market, By Treatment

38 North America Hemophilia Market, By Therapy

39 North America Hemophilia Market, By Distribution Channel

40 North America Hemophilia Market, By Country

41 U.S. Hemophilia Market, By Type

42 U.S. Hemophilia Market, By Treatment

43 U.S. Hemophilia Market, By Therapy

44 U.S. Hemophilia Market, By Distribution Channel

45 Canada Hemophilia Market, By Type

46 Canada Hemophilia Market, By Treatment

47 Canada Hemophilia Market, By Therapy

48 Canada Hemophilia Market, By Distribution Channel

49 Mexico Hemophilia Market, By Type

50 Mexico Hemophilia Market, By Treatment

51 Mexico Hemophilia Market, By Therapy

52 Mexico Hemophilia Market, By Distribution Channel

53 Four Quadrant Positioning Matrix

54 Company Market Share Analysis

55 Takeda Pharmaceutical Company Limited: Company Snapshot

56 Takeda Pharmaceutical Company Limited: SWOT Analysis

57 Takeda Pharmaceutical Company Limited: Geographic Presence

58 CSL Behring: Company Snapshot

59 CSL Behring: SWOT Analysis

60 CSL Behring: Geographic Presence

61 Pfizer, Inc.: Company Snapshot

62 Pfizer, Inc.: SWOT Analysis

63 Pfizer, Inc.: Geographic Presence

64 Bayer AG: Company Snapshot

65 Bayer AG: Swot Analysis

66 Bayer AG: Geographic Presence

67 BioMarin: Company Snapshot

68 BioMarin: SWOT Analysis

69 BioMarin: Geographic Presence

70 Sanofi: Company Snapshot

71 Sanofi: SWOT Analysis

72 Sanofi: Geographic Presence

73 Spark Therapeutics, Inc. : Company Snapshot

74 Spark Therapeutics, Inc. : SWOT Analysis

75 Spark Therapeutics, Inc. : Geographic Presence

76 F. Hoffmann La-Roche Ltd.: Company Snapshot

77 F. Hoffmann La-Roche Ltd.: SWOT Analysis

78 F. Hoffmann La-Roche Ltd.: Geographic Presence

79 Novo Nordisk A/S., Inc.: Company Snapshot

80 Novo Nordisk A/S., Inc.: SWOT Analysis

81 Novo Nordisk A/S., Inc.: Geographic Presence

82 Octapharma AG.: Company Snapshot

83 Octapharma AG.: SWOT Analysis

84 Octapharma AG.: Geographic Presence

85 Other Companies: Company Snapshot

86 Other Companies: SWOT Analysis

87 Other Companies: Geographic Presence

The Global Hemophilia Market has been studied from the year 2019 till 2028. However, the CAGR provided in the report is from the year 2023 to 2028. The research methodology involved three stages: Desk research, Primary research, and Analysis & Output from the entire research process.

The desk research involved a robust background study which meant referring to paid and unpaid databases to understand the market dynamics; mapping contracts from press releases; identifying the key players in the market, studying their product portfolio, competition level, annual reports/SEC filings & investor presentations; and learning the demand and supply-side analysis for the Hemophilia Market.

The primary research activity included telephonic conversations with more than 50 tier 1 industry consultants, distributors, and end-use product manufacturers.

Finally, based on the above thorough research process, an in-depth analysis was carried out considering the following aspects: market attractiveness, current & future market trends, market share analysis, SWOT analysis of the company and customer analytics.

We value your investment and offer free customization with every report to fulfil your exact research needs.

This website is secure and your personal details are safe. Privacy

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

What is the projected market size of the global hemophilia market?

The global hemophilia market is projected to grow at a CAGR of 6.8% from 2023 to 2028.

Who are the major vendors in the global hemophilia market?

What are the opportunities prevailing in the global hemophilia market?

Opportunities in the global hemophilia market include advancements in gene therapy, increasing focus on personalized treatments, expanding healthcare infrastructure in emerging markets, rising awareness leading to early diagnosis, and potential collaborations between pharmaceutical companies and healthcare providers to develop innovative therapies and improve patient care

What are the major drivers for the global hemophilia market growth?

Advancements in medical research, rising incidence of hemophilia, and increasing awareness and diagnosis are expected to support the market growth during the forecast period.